Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma
US7109223B2 · kind B2 · utility
5Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 25, 2003 |
| Grant date | Sep 19, 2006 |
| Priority date | — |
| Expiry date | Aug 25, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/10
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.